Search clinical trials for: CAD106

Total 7 results

Novartis Pharmaceuticals

Completed

Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients

Alzheimer's Disease

Belgium, Switzerland, Spain, United States, Italy, Sweden, Canada, Germany, Norway, Netherlands
Novartis

Completed

Safety and Tolerability of Repeated Subcutaneous Injections of CAD 106 in Mild Alzheimer's Patients

Alzheimer's Disease

United States
Novartis

Completed

Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Mild Alzheimer's Patients.

Alzheimer Disease

France, Sweden, Switzerland, United Kingdom
Novartis

Completed

To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients

Alzheimer Disease

United States
Novartis

Completed

To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients

Alzheimer Disease

France, United Kingdom, Sweden, Switzerland
Novartis Pharmaceuticals

Completed

Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease (AD)

Alzheimer's Disease

Sweden
Novartis Pharmaceuticals
National Institute on Aging (NIA); Amgen; Banner Alzheimer's Institute

Terminated

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (GS1)

Alzheimers Disease

United States, Belgium, United Kingdom, Germany, Australia, Canada, Spain, Finland, Switzerland, Netherlands

3

Subscribe